We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

4 hedge funds and large institutions have $38.7K invested in ZyVersa Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.08% more ownership

Funds ownership: 0.15% → 1.23% (+1.1%)

43% less funds holding

Funds holding: 7 → 4 (-3)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

54% less capital invested

Capital invested by funds: $84.9K → $38.7K (-$46.1K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
+$51.5K
2
Bank of America
Bank of America
North Carolina
+$38
3
JP Morgan Chase
JP Morgan Chase
New York
+$5

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$23.4K
2
CSS
Cubist Systematic Strategies
Connecticut
-$22K
3
UBS Group
UBS Group
Switzerland
-$14.9K
4
Jane Street
Jane Street
New York
-$9.09K
5
HF
HRT Financial
New York
-$9K

ZVSA Hedge Fund Activity: Q2 2024 in Review

4 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q2 2024, worth a combined $38.7K — down 54% from $84.9K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ZVSA and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $51.5K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $23.4K sold.

  • 4 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q2 2024, down from 7 in Q1 2024.
  • Funds reported $38.7K of ZyVersa Therapeutics stock for Q2 2024, down 54% quarter-over-quarter.
  • 3 funds opened new ZyVersa Therapeutics positions in Q2 2024 and 6 closed out, a net change of -3 holders.
  • The largest ZyVersa Therapeutics buyer in Q2 2024 was ADAR1 Capital Management, an estimated $51.5K added.
  • The largest ZyVersa Therapeutics seller in Q2 2024 was Two Sigma Securities, an estimated $23.4K sold.

Based on aggregated 13F filings for Q2 2024.